End-to-Trunk Masseteric to Facial Nerve Transfer With Selective Neurectomy for Facial Reanimation.

OBJECTIVE: To examine functional outcomes following end-to-trunk masseteric to facial nerve transfer in patients with chronic flaccid facial paralysis. DESIGN: Retrospective chart review. SETTING: Tertiary-care private practice setting. PARTICIPANTS: Patients with complete unilateral facial paralysis of less than 24 months duration. INTERVENTIONS: Direct end-to-trunk masseteric to facial nerve anastomosis. OUTCOME MEASURES: Outcome measures included time to first movement, development of synkinesis, and an objective assessment of the resting tone and dynamic movement that was achieved. RESULTS: Patient age at the time of transfer ranged from 6 to 61. Follow-up ranged from 12 to 24 months. No patients had any perioperative complications. No patient experienced significant mass movement or synkinetic facial movement with chewing. No patient had worsened chewing or swallowing. Patients have not yet recovered significant resting tone. All patients achieved smile activity when biting down with a median (interquartile range) oral commissure excursion of 7.57 mm (5.19-9.94 mm), starting 3 to 5 months after transfer. CONCLUSIONS: End-to-trunk masseteric to facial nerve transfer is a safe and effective procedure. Patients had rapid reinnervation with good excursion and achieved a natural appearing smile. The rehabilitated smile appears better than that achieved with hypoglossal-facial nerve transfer. The procedure can be performed coincident with cross-facial nerve grafting, and in some cases may produce dynamic facial movement that obviates the need for free muscle transfer.

Facial nerve management in patients with malignant skull base tumors.

INTRODUCTION: The course of the facial nerve through the cerebellopontine angle, temporal bone, and parotid gland puts the nerve at risk in cases of malignancy. In contrast to Bell's palsy, which presents with acute facial paralysis, malignancies cause gradual or fluctuating weakness. METHODS: We review malignancies affecting the facial nerve, including those involving the temporal bone, parotid gland, and cerebellopontine angle, in addition to metastatic disease. Intraoperative management of the facial nerve and long term management of facial palsy are reviewed. RESULTS: Intraoperative management of the facial nerve in cases of skull base malignancy may involve extensive exposure, mobilization, or rerouting of the nerve. In cases of nerve sacrifice, primary neurorrhaphy or interposition grafting may be used. Cranial nerve substitution, gracilis free functional muscle transfer, and orthodromic temporalis tendon transfer are management options for long term facial paralysis. CONCLUSION: Temporal bone, parotid gland, and cerebellopontine angle malignancies pose a tremendous risk to the facial nerve. When possible, the facial nerve is preserved. If the facial nerve is sacrificed, static and dynamic reanimation strategies are used to enhance facial function.

Oral squamous cell carcinoma: early detection and improved 5-year survival in 102 patients.

The 5-year survival rate for oral cancer remains poor, as a significant number of patients present with advanced disease at the time of diagnosis. The need remains for early detection within the context of routine oral examinations and evaluation of any noted clinical abnormalities. This retrospective study analyzed patient demographics, lesion characteristics, and 5-year survival rates associated with oral squamous cell carcinoma (OSCC) that was initially assessed using computer-assisted, 3-dimensional analysis of a transepithelial oral brush biopsy. Patients with oral lesions were initially assessed by community-based dentists and physicians using an oral brush biopsy. In 102 patients, OSCC was subsequently confirmed by incisional biopsy and histopathologic analysis. The majority of patients were without traditional risk factors. Almost half of the cancers presented as white lesions, and one-third presented as lesions smaller than 5 mm. In about three-fourths of all cases, OSCC initially presented without pain or bleeding. The overall 5-year survival rate for all patients was approximately 94%. Despite barriers to early detection, identification of early, asymptomatic OSCC with innocuous-appearing clinical features is achievable. This earlier detection can be expected to lead to a marked improvement in overall survival patterns.

Photobiomodulation therapy: management of mucosal necrosis of the oropharynx in previously treated head and neck cancer patients.

Necrosis of the oral mucosa following head and neck cancer radiation therapy presents considerable clinical management challenges. We report three cases of symptomatic persisting oral ulcerations where the addition of photobiomodulation therapy resulted in a rapid resolution of the oral lesions and in patient symptoms. These cases suggest that photobiomodulation may represent an adjunct to care of these difficult to manage complications in oncology.

A novel technique of Jones tube fixation for refractory tube extrusion.

One of the major complications of conjunctivodacryocystorhinostomy is Jones tube extrusion postoperatively. Various tube modifications have been described to promote tube stability. While these variants have been shown to be successful; on occasion, tube extrusion can be recurrent, leading to patient and surgeon frustration and ongoing symptoms. In this case report the author's describe a method of Jones tube fixation which mechanically prevents tube extrusion.

Single-incision sural nerve harvest: Technical considerations for cross-facial nerve grafting.

b.a. is the senior author and performed all of the procedures described, and conceptualized and edited the article. l.e.i. was responsible for data collection and analysis, editing the manuscript, and compiling the figures. d.b.y. performed the first single-incision nerve harvest with b.a. and is responsible for b.a. adopting the practice. b.l. is b.a.'s partner and assisted with the majority of surgeries and proofread the manuscript. g.g.m. was cosurgeon on many of the described cases and is partly responsible for conceptualizing the article. g.l.p. was responsible for data collection and writing of the original manuscript and compiling the illustrations. Laryngoscope, 129:2464-2466, 2019.

Modified Selective Neurectomy for the Treatment of Post-Facial Paralysis Synkinesis.

BACKGROUND: To address functional and smile dysfunction associated with post-facial paralysis synkinesis, the senior author (B.A.) has offered "modified selective neurectomy" of the lower division of the facial nerve as a long-term solution. This article examines technical considerations and outcomes of this procedure. METHODS: A retrospective review was conducted of patients who underwent modified selective neurectomy of buccal and cervical branches of the facial nerve performed by a single surgeon over a 4½-year period. House-Brackmann facial grading scores, electronic clinician-graded facial function scale, and onabotulinumtoxinA (botulinum toxin type A) dosages were examined before and after the procedure. RESULTS: Sixty-three patients underwent modified selective neurectomy between June 20, 2013, and August 12, 2017. There were no serious complications. The revision rate was 17 percent. Temporary oral incompetence was reported in seven patients (11 percent) postoperatively. A statistically significant improvement was achieved in electronic clinician-graded facial function scale analysis of nasolabial fold depth at rest, oral commissure movement with smile, nasolabial fold orientation with smile, nasolabial depth with smile, depressor labii inferioris lower lip movement, midfacial synkinesis, mentalis synkinesis, platysmal synkinesis, static score, dynamic score, synkinesis score, periocular score, lower face and neck score, and midface and smile score. There was a significant decrease in botulinum toxin type A dosage and House-Brackmann score after surgery. CONCLUSION: Modified selective neurectomy of the buccal and cervical divisions of the facial nerve is an effective long-term treatment for smile dysfunction in patients with post-facial paralysis synkinesis. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.

Parotidectomy for Benign Parotid Tumors.

Parotidectomy for benign tumors is undergoing constant evolution. The potential for recurrence and malignant transformation of pleomorphic adenomas creates complexities that have forced head and neck surgeons to undertake more comprehensive parotid surgery with facial nerve dissection. This approach carries inherent morbidities, including facial nerve injury, Frey syndrome, and facial asymmetry, that have to be addressed. Extracapsular dissection is compared with conventional superficial parotidectomy; surgical histologic findings are discussed as well as outcome data. More novel approaches are discussed as well. This article provides a systematic approach to benign parotid tumor surgery.

Facial Nerve and Parotid Gland Anatomy.

This article provides an overview of important anatomic and functional anatomy associated with the parotid gland and facial nerve for the practicing otolaryngologist, head and neck surgeon, facial plastic surgeon, and plastic surgeon. The discussion includes the important anatomic relationships and physiology related to the parotid gland and salivary production. A comprehensive description of the path of facial nerve, its branches, and important anatomic landmarks also are provided.

Locoregional Parotid Reconstruction.

Parotidectomy for benign and malignant tumors often results in conspicuous contour abnormalities and soft tissue defects. Immediate reconstruction leads to improved patient satisfaction and local or regional flaps can be used for reconstruction in most cases. This article provides a systematic approach to parotid reconstruction.

Long-term survival outcome in transhyoid resection of base of tongue squamous cell carcinoma.

BACKGROUND: The transhyoid approach for the resection of squamous cell carcinoma (SCC) of the base of the tongue continues to evolve and remains controversial. We previously reported that the functional outcome of this operation is superior to that of the traditional transmandibular approaches. OBJECTIVE: To report our long-term survival rates for T1, T2, and select T3 SCCs of the base of the tongue using the transhyoid approach. PATIENTS AND METHODS: Twenty-eight patients with SCC of the base of the tongue were treated using a transhyoid approach at the University of California, Los Angeles, Medical Center between 1981 and 1998. RESULTS: All 28 patients underwent simultaneous neck dissection, and 27 patients underwent postoperative radiation therapy. The majority of the patients had advanced stage III or IV SCC. Twenty-five of the 28 patients had clear margins in the final pathologic specimen. The overall 3- and 5-year patient survival rates were 88.5% and 80.0%, respectively. Tumor-specific 5-year survival rates were 80.0%, 84.6%, and 50.0% for T1, T2, and T3 tumors, respectively. Stage-specific 5-year survival rates were 60.0%, 100.0%, and 80.0% for stages II, III, and IV, respectively. CONCLUSIONS: The advantages of the transhyoid approach to SCC of the base of the tongue in conjunction with neck dissection and postoperative radiation therapy include excellent long-term patient survival, improved swallowing and speech function, outstanding tumor exposure, and minimal cosmetic deformity.

Inhibitors of nitric oxide promote microvascular thrombosis.

BACKGROUND: Microvascular free tissue transfer is a widely utilized method of head and neck reconstruction. Despite advances in the field, reports of experienced microvascular surgeons on large series of free flap procedures reveal that the incidence of free flap failure varies between 5% and 9%. Most cases of free flap failure are initiated by platelet-mediated events that result in thrombosis at the microvascular anastomoses. Recent evidence indicates that nitric oxide (NO) plays a critical role in preventing thrombosis by inhibiting platelet adhesion and aggregation. The role of NO in microvascular anastomotic thrombosis has not been studied. OBJECTIVE: To determine the role of NO in microvascular thrombosis using an in vivo rabbit model. METHODS: An arterial inversion graft (AIG)-induced microvascular thrombosis model was utilized in New Zealand white rabbits. The femoral arteries were used bilaterally to create 3-mm AIGs. Intravenous NO donor, NO inhibitor, or isotonic sodium chloride solution (control) was administered for 1 hour following the completion of the AIG, and vessel patency was then checked using a direct "milking test." Sixteen rabbits (32 AIGs) were used as controls. A potent NO inhibitor, N(w)-nitro-L-arginine methylester (L-NAME), was administered to 13 rabbits (26 AIGs) and L-arginine, a NO precursor/donor, was given to 10 rabbits (20 AIGs). RESULTS: The control animals had a thrombosis rate of 46.9%. The rate of thrombosis in animals exposed to an NO inhibitor (L-NAME) was significantly higher, at 76.9% (P<.05, chi( 2) = 4.23). The L-arginine group did not show a statistical difference with the control in the rate of thrombosis (50.0%). CONCLUSIONS: Nitric oxide plays a role in microvascular anastamotic thrombosis. Intravenous NO inhibitors appear to increase the short-term rate of microvascular thrombosis. L-arginine, an NO precursor, does not appear to produce the opposite effect. Further studies using local NO donors and antagonists as well as more potent NO precursors are needed to further evaluate NO's role in microvascular thrombosis. The results of this study may have applications to human microvascular surgery.